Cancer Genetic Counseling and Testing: Perspectives of Epithelial Ovarian Cancer Patients and Gynecologic Oncology Healthcare Providers
- PMID: 28785836
- DOI: 10.1007/s10897-017-0135-2
Cancer Genetic Counseling and Testing: Perspectives of Epithelial Ovarian Cancer Patients and Gynecologic Oncology Healthcare Providers
Abstract
Multi-gene panel testing has expanded the genetic information available to cancer patients. The objective was to assess provider behaviors and attitudes and patient knowledge and attitudes towards genetic counseling and testing. An online survey was distributed to Society of Gynecologic Oncology members and a written questionnaire was administered to patients diagnosed with epithelial ovarian cancer at a tertiary care referral center. Most of the 233 (18% response rate) provider respondents were gynecologic oncologists. Access to a genetic counselor was reported by 87% of providers and 55% deferred all testing to genetic counselors. Of 53 ovarian cancer patient respondents, two-thirds had previously seen a genetic counselor or undergone testing. Patients' attitudes about genetic counseling and/or testing were favorable with respect to themselves (70-81%) and their family members (94%). Less than 25% of patients indicated worrying about health care discrimination, lack of privacy, or high cost. Seventy-seven percent of patients demonstrated a desire to obtain genetic information even if the results were not currently actionable, and 20% of providers stated they test for only those genes with guideline-supported actionable results. Provider practice differences were identified in screening and prevention strategies for patients with deleterious non-BRCA mutations and variants of uncertain significance. The variation in clinical interpretation of results associated with poorly defined cancer risks signals a need for more comprehensive training and guidelines to ensure access to evidence-based care.
Keywords: Genetic counseling; Genetic testing; Moderate penetrance gene; Ovarian cancer; Panel testing; Variant of uncertain significance.
Similar articles
-
Implementation of a quality improvement project for universal genetic testing in women with ovarian cancer.Gynecol Oncol. 2018 Jun;149(3):565-569. doi: 10.1016/j.ygyno.2018.03.059. Epub 2018 Apr 10. Gynecol Oncol. 2018. PMID: 29653687
-
Facilitated referral pathway for genetic testing at the time of ovarian cancer diagnosis: uptake of genetic counseling and testing and impact on patient-reported stress, anxiety and depression.Gynecol Oncol. 2020 Apr;157(1):280-286. doi: 10.1016/j.ygyno.2020.01.007. Epub 2020 Feb 11. Gynecol Oncol. 2020. PMID: 32057464 Clinical Trial.
-
"I think that a brief conversation from their provider can go a very long way": Patient and provider perspectives on barriers and facilitators of genetic testing after ovarian cancer.Support Care Cancer. 2021 May;29(5):2663-2677. doi: 10.1007/s00520-020-05779-1. Epub 2020 Sep 25. Support Care Cancer. 2021. PMID: 32975643 Free PMC article.
-
Inadequate Rates of BRCA Testing with its Negative Consequences for Women with Epithelial Ovarian Cancer and their Families: an Overview of the Literature.Clin Oncol (R Coll Radiol). 2018 Aug;30(8):472-483. doi: 10.1016/j.clon.2018.04.004. Epub 2018 May 5. Clin Oncol (R Coll Radiol). 2018. PMID: 29735311 Review.
-
Genetic counseling, testing, and screening for breast and ovarian cancer: practical and social considerations.Curr Womens Health Rep. 2002 Jun;2(3):163-9. Curr Womens Health Rep. 2002. PMID: 12099190 Review.
Cited by
-
Exploring Literacy and Knowledge Gaps and Disparities in Genetics and Oncogenomics Among Cancer Patients and the General Population: A Scoping Review.Healthcare (Basel). 2025 Jan 9;13(2):121. doi: 10.3390/healthcare13020121. Healthcare (Basel). 2025. PMID: 39857147 Free PMC article. Review.
-
Implementation of Pharmacogenomics Testing in Daily Clinical Practice: Perspectives of Prescribers from Two Canadian Armed Forces Medical Clinics.J Pers Med. 2025 Mar 4;15(3):101. doi: 10.3390/jpm15030101. J Pers Med. 2025. PMID: 40137417 Free PMC article.
-
Identifying Mediators of Intervention Effects Within a Randomized Controlled Trial to Motivate Cancer Genetic Risk Assessment Among Breast and Ovarian Cancer Survivors.Ann Behav Med. 2023 Oct 16;57(11):965-977. doi: 10.1093/abm/kaad048. Ann Behav Med. 2023. PMID: 37658805 Free PMC article. Clinical Trial.
-
Building a Personalized Medicine Infrastructure for Gynecological Oncology Patients in a High-Volume Hospital.J Pers Med. 2021 Dec 21;12(1):3. doi: 10.3390/jpm12010003. J Pers Med. 2021. PMID: 35055317 Free PMC article. Review.
-
Patterns and predictors of genetic referral among ovarian cancer patients at a National Cancer Institute-Comprehensive Cancer Center.Clin Genet. 2020 Feb;97(2):370-375. doi: 10.1111/cge.13654. Epub 2019 Nov 24. Clin Genet. 2020. PMID: 31600840 Free PMC article.
References
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical